Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 1;58(3):353-7.
doi: 10.1097/QAI.0b013e31822d4063.

Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana

Scott Dryden-Peterson  1 , Oluwemimo Jayeoba, Michael D Hughes, Haruna Jibril, Koona Keapoletswe, Josephine Tlale, Taolo A Modise, Aida Asmelash, Sikhulile Moyo, Erik van Widenfelt, Joseph Makhema, Max Essex, Roger L Shapiro, Shahin Lockman
Affiliations

Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana

Scott Dryden-Peterson et al. J Acquir Immune Defic Syndr. .

Abstract

Few studies have compared the programmatic effectiveness of the recommended strategies of antenatal highly active antiretroviral therapy (HAART) and zidovudine for prevention of mother-to-child transmission. We prospectively followed infants (93% formula fed) whose mothers who took either HAART (258 infants) or zidovudine (170 infants) during pregnancy in the Botswana national program. Overall, 10 infants (2.5%) acquired HIV--9 infants in the zidovudine group (5.5%, 95% confidence interval: 2.6% to 10.2%) and 1 infant in the HAART group (0.4%, 95% confidence interval: 0.0% to 2.2%). Maternal HAART was associated with decreased prevention of mother-to-child transmission (P = 0.001) and improved HIV-free survival (P = 0.040) compared with zidovudine (with or without single-dose nevirapine) in a programmatic setting.

PubMed Disclaimer

References

    1. WHO . Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Recommendations for a public heath approach. World Health Organization; Geneva: 2010. - PubMed
    1. European Collaborative Study Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005 Feb 1;40(3):458–465. - PubMed
    1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484–494. - PubMed
    1. Gaolathe T, Tlale J, Keapoletswe K, et al. Mother-to-Child HIV Transmission Rate in Botswana - Analysis of Dried Blood Spot (DBS) Results from the National PMTCT Programme. 4th IAS Conference on HIV Treatment, Pathogenesis and Prevention; Vol Mexico City. 2008.
    1. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010 Jun 17;362(24):2282–2294. - PMC - PubMed

Publication types

MeSH terms